BIOMAT Database Logo BIOMAT Database Logo

Factors affecting treatment responses to interferon-alpha in chronic hepatitis C. 1996

J M Pawlotsky, and F Roudot-Thoraval, and A Bastie, and F Darthuy, and J Rémiré, and J M Métreau, and E S Zafrani, and J Duval, and D Dhumeaux
Department of Bacteriology, Hôpital Henri Mondor, Université Paris-XII, Créteil, France.

Parameters have been studied to predict responses to interferon (IFN) therapy for chronic hepatitis C, but the definition of a response, the times at which responses were assessed, and the pretreatment parameters considered differ markedly from study to study. Thus, 113 patients with chronic hepatitis C were treated 3-6 months with 3 MU of IFN-alpha 2a three times a week and assessed for pretreatment parameters predictive of responses to IFN. In a multivariate analysis, a biochemical response (normal aminotransferase activity) at the end of treatment was significantly associated with low body weight, normal gamma-glutamyl transpeptidase activity, and a pretreatment hepatitis C virus (HCV) genotype other than 1. Six months after the end of treatment, a low virus burden and a lack of anti-HCV IgM core antibodies were independently associated with sustained virologic response (i.e., normal aminotransferase activity and HCV RNA negativity). Therefore, these pretreatment parameters should be taken into account when individual treatment protocols are designed.

UI MeSH Term Description Entries
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D005260 Female Females
D005723 gamma-Glutamyltransferase An enzyme, sometimes called GGT, with a key role in the synthesis and degradation of GLUTATHIONE; (GSH, a tripeptide that protects cells from many toxins). It catalyzes the transfer of the gamma-glutamyl moiety to an acceptor amino acid. GGTP,Glutamyl Transpeptidase,gammaglutamyltransferase,gamma-Glutamyl Transpeptidase,Transpeptidase, Glutamyl,Transpeptidase, gamma-Glutamyl,gamma Glutamyl Transpeptidase,gamma Glutamyltransferase
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes

Related Publications

J M Pawlotsky, and F Roudot-Thoraval, and A Bastie, and F Darthuy, and J Rémiré, and J M Métreau, and E S Zafrani, and J Duval, and D Dhumeaux
[Predictive factors of response to interferon-alpha treatment in chronic hepatitis C].
July 1997, Revista espanola de enfermedades digestivas,
J M Pawlotsky, and F Roudot-Thoraval, and A Bastie, and F Darthuy, and J Rémiré, and J M Métreau, and E S Zafrani, and J Duval, and D Dhumeaux
[Interferon alpha treatment in chronic hepatitis C].
January 1992, Giornale di batteriologia, virologia ed immunologia,
J M Pawlotsky, and F Roudot-Thoraval, and A Bastie, and F Darthuy, and J Rémiré, and J M Métreau, and E S Zafrani, and J Duval, and D Dhumeaux
Alpha interferon treatment in chronic hepatitis C.
January 1995, Clinical and experimental rheumatology,
J M Pawlotsky, and F Roudot-Thoraval, and A Bastie, and F Darthuy, and J Rémiré, and J M Métreau, and E S Zafrani, and J Duval, and D Dhumeaux
Virological and biochemical responses to interferon-alpha in chronic hepatitis C.
January 1994, Lancet (London, England),
J M Pawlotsky, and F Roudot-Thoraval, and A Bastie, and F Darthuy, and J Rémiré, and J M Métreau, and E S Zafrani, and J Duval, and D Dhumeaux
Alpha interferon treatment of chronic hepatitis C.
January 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
J M Pawlotsky, and F Roudot-Thoraval, and A Bastie, and F Darthuy, and J Rémiré, and J M Métreau, and E S Zafrani, and J Duval, and D Dhumeaux
[Chronic hepatitis C and interferon alpha treatment].
May 1995, Pediatria polska,
J M Pawlotsky, and F Roudot-Thoraval, and A Bastie, and F Darthuy, and J Rémiré, and J M Métreau, and E S Zafrani, and J Duval, and D Dhumeaux
Treatment of interferon-alpha for chronic hepatitis C.
June 2006, Expert opinion on pharmacotherapy,
J M Pawlotsky, and F Roudot-Thoraval, and A Bastie, and F Darthuy, and J Rémiré, and J M Métreau, and E S Zafrani, and J Duval, and D Dhumeaux
[Treatment of chronic hepatitis C with interferon alpha].
January 1991, Gastroenterologie clinique et biologique,
J M Pawlotsky, and F Roudot-Thoraval, and A Bastie, and F Darthuy, and J Rémiré, and J M Métreau, and E S Zafrani, and J Duval, and D Dhumeaux
Treatment of chronic hepatitis C with alpha-interferon.
January 1991, Journal of gastroenterology and hepatology,
J M Pawlotsky, and F Roudot-Thoraval, and A Bastie, and F Darthuy, and J Rémiré, and J M Métreau, and E S Zafrani, and J Duval, and D Dhumeaux
Treatment of chronic hepatitis C with interferon alpha.
March 1995, The New Zealand medical journal,
Copied contents to your clipboard!